All Releases
 |
Tercica Announces Results from Increlex(R) Phase IIIb Study Demonstrating Dose-Dependent Height Velocity Increase in Primary IGFD Short Stature Population and Other Increlex(R) Studies at the 13th International Congress of Endocrinology Meeting
Nov 12, 2008
|
19.7 KB |
| |
BRISBANE, Calif., Nov 12, 2008 (BUSINESS WIRE) -- Tercica, Inc., a wholly-owned subsidiary of Ipsen (Euronext: IPN) today announced Phase IIIb clinical trial results demonstrating that Increlex(R) (mecasermin (rDNA origin) injection) achieved statistically significant dose-dependent first-year height velocity increases in children with Primary IGF-...
|
|
Tercica Reports Second Quarter 2008 Financial Results
Jul 31, 2008
|
15.9 KB |
| |
BRISBANE, Calif., Jul 31, 2008 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq: TRCA) today announced financial results for the quarter ended June 30, 2008. Net product sales totaled $6.2 million, compared to $2.0 million in the second quarter of 2007. Net product sales for Increlex(R) and Somatuline(R) Depot in the second quarter of 2008 were $4.6 millio...
|
|
Tercica Announces Results from Increlex(R) IGFD Patient Registry and Other Increlex(R) Studies at the 90th Meeting of the Endocrine Society
Jun 16, 2008
|
15.5 KB |
| |
BRISBANE, Calif., Jun 16, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ: TRCA) today announced the first results from the Increlex(R) Growth Forum Database (IGFD) Registry in two posters presented at the 90th annual meeting of the Endocrine Society in San Francisco. Increlex(R) (mecasermin (rDNA origin) injection) is currently approved in the Unite...
|
|
Ipsen to Acquire Tercica
Jun 4, 2008
|
14.3 KB |
| |
BRISBANE, Calif., Jun 04, 2008 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq: TRCA) today announced that Tercica and Ipsen, S.A. (Euronext: IPN) have entered into a definitive merger agreement by which an affiliate of Ipsen would acquire all of the shares of Tercica common stock that Ipsen does not currently own at a price of $9.00 per share in cash, wh...
|
|
Tercica to Present at FBR Capital Markets 12th Annual Spring Investor Conference
May 21, 2008
|
7.5 KB |
| |
BRISBANE, Calif., May 21, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ: TRCA) today announced that company management will present at the FBR Capital Markets 12th Annual Spring Investor Conference on Wednesday, May 28, 2008 at 2:20 p.m. Eastern time. The conference will be held at the Grand Hyatt New York.
Interested individuals may access a l...
|
|
Tercica Reports First Quarter 2008 Financial Results
May 12, 2008
|
14.7 KB |
| |
BRISBANE, Calif., May 12, 2008 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced financial results for the quarter ended March 31, 2008. Total net product sales totaled $4.3 million, compared to $1.1 million in the first quarter of 2007. Net product sales for Increlex(R) and Somatuline(R) Depot in the first quarter 2008 were $3.4 milli...
|
|
Tercica to Hold 2008 First Quarter Financial Results Conference Call May 12
May 1, 2008
|
7.7 KB |
| |
BRISBANE, Calif., May 01, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ: TRCA) today announced the Company will release its 2008 first quarter financial results after market close on Monday, May 12, 2008.
Management will host an investment community conference call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on Monday, May 12, ...
|
|
Tercica to Present at March Investment Conferences
Mar 10, 2008
|
7.8 KB |
| |
BRISBANE, Calif., Mar 10, 2008 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq: TRCA) today announced that company management will make the following investment community presentations:
-- Cowen & Company 28th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston on Monday, March 17 at 4:00 p.m. Eastern time (1:00 p.m....
|
|
Tercica Announces Changes to Its Board of Directors and Management Team
Feb 29, 2008
|
8.2 KB |
| |
BRISBANE, Calif., Feb 29, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that it has named Richard King as President and Chief Operating Officer. Previously, Mr. King was Tercica's Chief Operating Officer. John A. Scarlett, M.D., will remain as the Chief Executive Officer of Tercica. The Company also announced that Ajay Bansal ...
|
|
Tercica Reports Fourth Quarter and Year-End 2007 Financial Results
Feb 27, 2008
|
16.7 KB |
| |
BRISBANE, Calif., Feb 27, 2008 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq: TRCA) today announced financial results for the quarter and year ended December 31, 2007. Net product sales for the quarter ended December 31, 2007 totaled $3.8 million. The net loss for the quarter was $18.7 million, or $0.36 per share, compared to a net loss of $41.0 million...
|
|
Tercica to Hold 2007 Fourth Quarter and Year-End Financial Results Conference Call February 27
Feb 20, 2008
|
7.8 KB |
| |
BRISBANE, Calif., Feb 20, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced the Company will release its 2007 fourth quarter and year-end financial results before market open on Wednesday, February 27, 2008.
Management will host an investment community conference call beginning at 9:00 a.m. Eastern time (6:00 a.m. Pacific time...
|
|
Tercica Initiates Phase II Clinical Trial with Next-Generation Growth Hormone Product for the Treatment of Short Stature
Jan 22, 2008
|
10.2 KB |
| |
BRISBANE, Calif., Jan 22, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ: TRCA) today announced that the Company has begun dosing the first patient in a Phase II clinical study evaluating the combination of Genentech, Inc.'s recombinant human growth hormone Nutropin AQ(R) (somatropin (rDNA origin)) and Tercica's recombinant insulin-like growth facto...
|
|
Tercica Reports Third Quarter 2007 Financial Results
Nov 1, 2007
|
15.8 KB |
| |
BRISBANE, Calif., Nov 01, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced financial results for the quarter ended September 30, 2007. Net product sales totaled $2.9 million, compared with $316,000 in the third quarter of 2006. Total net revenues for the quarter totaled $23.4 million, including a licensing milestone of $20.3 mill...
|
|
Tercica to Hold 2007 Third Quarter Financial Results Conference Call November 1
Oct 30, 2007
|
7.8 KB |
| |
BRISBANE, Calif., Oct 30, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced the Company will release its 2007 third quarter financial results after market close on Thursday, November 1, 2007.
Management will host an investment community conference call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on Thursday, N...
|
|
Tercica to Present at November Investment Conferences
Oct 29, 2007
|
7.5 KB |
| |
BRISBANE, Calif., Oct 29, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that Company management will make presentations at the following investment conferences in November:
-- Rodman and Renshaw Acumen BioFin 9th Annual Healthcare conference being held at the Palace Hotel in New York on Tuesday, November 6, 2007 at 11:40 a...
|
|
Tercica to Present at the BIO Investor Forum on October 10
Oct 2, 2007
|
7.4 KB |
| |
BRISBANE, Calif., Oct 02, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that Company management will make an investment community presentation at the BIO Investor Forum at the Palace Hotel in San Francisco. Tercica's presentation will begin at 2:15 p.m. Pacific time (5:15 p.m. Eastern time) on Wednesday, October 10, 2007.
...
|
|
Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
Aug 30, 2007
|
15.3 KB |
| |
BRISBANE, Calif., Aug 30, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that its partner Ipsen (Euronext:IPN) has received notice of approval from the U.S. Food and Drug Administration (FDA) for marketing Somatuline(R) Depot (lanreotide) injection 60, 90 and 120 mg/ml in the United States.
Somatuline(R) Depot is indicated ...
|
|
Tercica to Present at the BioCentury and Thomson Financial NewsMakers in the Biotech Industry Conference on September 6
Aug 27, 2007
|
7.5 KB |
| |
BRISBANE, Calif., Aug 27, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that Company management will make an investment community presentation at the BioCentury and Thomson Financial NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York. Tercica's presentation will begin...
|
|
Tercica Receives Marketing Approval for Increlex in the European Union
Aug 8, 2007
|
11.9 KB |
| |
BRISBANE, Calif., Aug 08, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced that the European Commission has granted marketing authorization for Increlex(R) (mecasermin) 10 mg/ml solution for injection. The authorized indication is for the long-term treatment of growth failure in children and adolescents with severe primary insuli...
|
|
Tercica Reports Second Quarter 2007 Financial Results
Aug 2, 2007
|
14.4 KB |
| |
BRISBANE, Calif., Aug 02, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced financial results for the quarter ended June 30, 2007. Net product sales totaled $2.0 million, compared to $166,000 in the second quarter of 2006. Net loss for the quarter was $12.8 million, or $0.26 per share, compared to a net loss of $14.7 million, or $...
|
|
|
